Literature DB >> 1328843

Gate-dependent blockade of sodium channels by phenothiazine derivatives: structure-activity relationships.

V Bolotina1, K R Courtney, B Khodorov.   

Abstract

Voltage-clamp studies of myelinated nerve fibers that are designed to determine structural criteria regarding selective drug blocking of open and inactive states of the sodium channel are described. A series of phenothiazines were studied. It was shown that two of these drugs (ethmozine and ethacizine, at 5 microM) require open channels for blocking action and the other two (chlorpromazine and chloracizine, at 5 microM) can effectively block inactive channels. A size criterion, which looks at the spanning width at the aromatic end of these molecules, can explain this qualitative difference in drug action. Other important differences in the action of these four drugs are described, including their rates of development of drug block and removal of drug block. Relevant critiques of proposed structure-activity hypotheses are given.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1328843

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  3 in total

1.  Chlorpromazine inhibits miniature GABAergic currents by reducing the binding and by increasing the unbinding rate of GABAA receptors.

Authors:  J W Mozrzymas; A Barberis; K Michalak; E Cherubini
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

2.  Block of potassium currents in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds.

Authors:  J R Wooltorton; A Mathie
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

3.  Impact of synaptic neurotransmitter concentration time course on the kinetics and pharmacological modulation of inhibitory synaptic currents.

Authors:  Andrea Barberis; Enrica Maria Petrini; Jerzy W Mozrzymas
Journal:  Front Cell Neurosci       Date:  2011-06-22       Impact factor: 5.505

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.